IBO

Impact BioMedical is not an operating company in any conventional sense — it is a patent-holding shell that "discovers, confirms, and patents" compounds (Linebacker, Laetose, 3F, Equivir) and hopes to monetize them through licensing, milestones and royalties from partners like ProPhase Labs. The numbers confirm there is no business yet: FY2025 revenue was $32.0K — down 36% YoY — against a net loss of $11.8M, producing a net margin of -36,994% and a P/S of 1,590x. Four years of history show revenue never exceeding $50K while cumulative losses drove retained earnings to -$49.5M. This is a binary, lottery-ticket outcome dependent on partner-driven clinical and commercial success that the filing itself warns is unlikely: "Only a very few biopharmaceutical research and development programs result in commercially viable products."

The balance sheet turns speculation into distress. Cash and equivalents collapsed to $3.00K (down 99.8%), while operations burned $1.89M in cash during the year — there is effectively no runway, so continued dilutive financing is a near-certainty. Shares outstanding already ballooned 792% YoY to 108M, and current assets of $411K sit below current liabilities of $1.16M (negative working capital). The headline improvements — equity up 196% to $12.6M and liabilities down 86% — reflect balance-sheet restructuring and IP carrying value, not cash generation; total assets still fell 14% and $17.4M of assets are backstopped by only $3K of actual cash. ROE of -93.9% underscores that the equity is being incinerated.